FDA Accepts sNDA for Brukinsa in Waldenström Macroglobulinemia
The FDA has accepted a supplemental new drug application (sNDA) for brukinsa for the treatment of adults with Waldenström Macroglobulinemia (WM).
Hematologic Cancers
American Society of Hematology Releases Updated Guidelines for Treating Newly Diagnosed AML in Older Adults
This review of the guidelines is presented as 6 questions and answers that help direct treatment decision for patients 65 and older with newly diagnosed AML.
Ukoniq Approved for Marginal Zone Lymphoma, Follicular Lymphoma
The approval was based on data from the open-label, multi-cohort phase 2 UNITY-NHL Trial.
10-Gene Sequencing Panel Could Identify Patients With MDS Likely to Relapse After Allogeneic HCT
Investigators tested the utility of ultra-deep genomic testing to predict relapse in patients with myelodysplastic syndrome initiating conditioning therapy for allogeneic hematopoietic cell transplant (alloHCT).
Waldenström Macroglobulinemia 2020 Year-End Update: Diagnosis and Treatment Considerations
A year-end update on WM, a distinct entity of lymphoplasmacytic lymphoma presenting with monoclonal pleomorphic immunoglobulin M (IgM) proteins, was recently published in the American Journal of Hematology.
Mortality Risk With COVID-19 in Patients With Myeloproliferative Neoplasms
Observational, retrospective study revealed factors that may be linked to higher mortality risk in patients with MPN and COVID-19.
Considerations for Secondary Primary Malignancy Development in Follicular Lymphoma
As follicular lymphoma (FL) survival rates have improved, concern that patients are at increased risk for the development of a secondary primary malignancy (SPM) has arisen.
Bystander Killing Could Be Key Factor in CAR-T Success in Non-Hodgkin Lymphoma
Chimeric antigen receptor (CAR)-T cells can kill off-target tumor cells in the vicinity of the target cells, a phenomenon known as bystander killing. Modulating the expression of the protein mediating this process—Fas—could be a strategy to improve CAR-T efficacy.
Cost a Barrier to Daratumumab-Containing Regimens in First-Line Treatment of Multiple Myeloma
A cost analysis shows daratumumab may be better used as a second-line treatment for transplant-ineligible patients with multiple myeloma.
Addition of Elotuzumab to RVd Does Not Improve Outcomes in High-Risk Multiple Myeloma
Investigators compared elotuzumab plus lenalidomide, bortezomib, and dexamethasone (RVd) with RVd alone in the induction and maintenance therapy settings.
-
Loading...
-
Loading...
Next post in General Hematology
